Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 7/20 | 0.36 |
| ▸ | MME | P08473 | 6/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28364743 | 0.70 | MEN1 (0.40) | ALDH1A1NPC1RAB9ANPSR1 | |
| SCHEMBL15912446 | 0.69 | TNIK (0.32) | TP53 | |
| SCHEMBL14498353 | 0.68 | PTGS1 (0.40) | ALDH1A1NPC1RAB9ANPSR1 | |
| SCHEMBL25922341 | 0.66 | CYP1A2 (0.51) | CYP1A2 | |
| SCHEMBL5790978 | 0.64 | CYP1A2 (0.43) | CYP1A2ECE1MMEAGTR2MMEL1 | |
| SCHEMBL13090823 | 0.64 | — | — | |
| SCHEMBL16509726 | 0.64 | — | — | |
| SCHEMBL12868224 | 0.62 | TP53 (0.67) | TP53ALDH1A1NPC1RAB9ANPSR1 | |
| SCHEMBL23469441 | 0.61 | NAALAD2 (0.40) | TP53CYP1A2ALDH1A1HCAR3HCAR2 | |
| SCHEMBL25146364 | 0.61 | TP53 (0.65) | TP53ALDH1A1NPC1RAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | CCR8, CCR1, CCR3 | TP53 465/4885CYP1A2 2414/4885ECE1 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.